EUVIMEDEUVIMED entdecken
Crossref

Discordant Treatment Goals for Patients With Atrial Fibrillation and Clinical Trials Metrics

Brian Zenger, John A Spertus, Michael Torre, Ann Lyons, T Jared Bunch, Rachel Hess, Yue Zhang, Jonathan P Piccini, Morgan M Millar, Trudie Lobban, Benjamin A Steinberg

JACC: Clinical Electrophysiology · 2024

DOI: 10.1016/j.jacep.2024.06.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2024. Verfasst von Brian Zenger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Patient Reported Outcome Measures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Most clinical trials define successful atrial fibrillation (AF) treatment as no AF episodes longer than 30 seconds. Yet, there has been minimal study of how patients define successful treatment and whether their perspectives align with trial outcomes. OBJECTIVES: Survey patients with AF to identify: 1) what aspect of AF is most important to address (frequency, duration, or severity of AF episodes); 2) what AF burden would be considered acceptable to consider treatment successful; and 3) to establish patient preferences for successful treatment thresholds for a validated patient-reported outcome (PRO) score. METHODS: We surveyed patients receiving active care for AF at a single tertiary care center modeled after the Toronto AF Severity Scale (AFSS). The survey consisted of current and "successful treatment" AF frequency, burden, and symptom domains; and baseline socioeconomic information. RESULTS: Of 7,000 invitations, 852 individuals completed the survey (12% response) with a mean age of 65 ± 13 years, 36.5% were female, and they had a mean CHA2DS2-VAsc score of 2.9 ± 1.9. Overall, 114 (13%) selected a decrease in AF episode duration as their top treatment priority, 505 (59%) episode frequency, and 230 (27%) episode severity. Overall, 207 (24%) patients would only consider a treatment successful if they never had AF again, whereas 645 (76%) patients considered success to be fewer AF episodes. A total of 341 (40%) patients would only consider a treatment successful if AF episodes lasted less than a few minutes, whereas 509 (60%) patients would accept AF episodes lasting >30 minutes. An AFSS symptom score ≤5 was considered a good outcome by 80% of respondents. CONCLUSIONS: Patients prioritize decreased AF frequency over improvements in severity or duration, and an AFSS ≤5 would be a reasonable outcome of AF treatment. Most patients would consider treatment successful if they had more than 1 AF episode lasting longer than 30 seconds. Future clinical trial design should consider patients' perspectives when designing outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationPatient Reported Outcome MeasuresHumansFemaleMaleAgedMiddle AgedClinical Trials as TopicPatient PreferenceSurveys and QuestionnairesTreatment OutcomeSeverity of Illness Index

Stichwörter der Autor:innen

Toronto AFSSatrial fibrillationcardiac arrhythmiahealth-related quality of lifepatient preferencespatient-reported outcomessurvey

Autor:innen und Institutionen

  • Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
  • University of Missouri-Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City Missouri, USA.
  • University of Utah Health, Salt Lake City, Utah, USA.
  • Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
  • Arrhythmia Alliance, Stratford-upon-Avon, United Kingdom.
  • University of Utah Health, Salt Lake City, Utah, USA. Electronic address: benjamin.steinberg@hsc.utah.edu.

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Zenger, B., Spertus, J. A., Torre, M., Lyons, A., Bunch, T. J., Hess, R., Zhang, Y., Piccini, J. P., Millar, M. M., Lobban, T., & Steinberg, B. A. (2024). Discordant Treatment Goals for Patients With Atrial Fibrillation and Clinical Trials Metrics. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2024.06.026

Vancouver

Zenger B, Spertus JA, Torre M, Lyons A, Bunch TJ, Hess R, et al. Discordant Treatment Goals for Patients With Atrial Fibrillation and Clinical Trials Metrics. JACC: Clinical Electrophysiology. 2024. doi:10.1016/j.jacep.2024.06.026

BibTeX
@article{Zenger2024,
  author = {Zenger, Brian and Spertus, John A and Torre, Michael and Lyons, Ann and Bunch, T Jared and Hess, Rachel and Zhang, Yue and Piccini, Jonathan P and Millar, Morgan M and Lobban, Trudie and Steinberg, Benjamin A},
  title = {Discordant Treatment Goals for Patients With Atrial Fibrillation and Clinical Trials Metrics},
  journal = {JACC: Clinical Electrophysiology},
  year = {2024},
  doi = {10.1016/j.jacep.2024.06.026}
}
Kostenlos starten →